Clinical trials: sponsored by Tang-Du Hospital
Non-small Cell Lung Cancer
A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC
This study utilized a prospective cohort design. It is proposed to analyze the serum of NSCLC patients treated with chemotherapy combined with immunotherapy, and chemotherapy alone, starting from liquid biopsy technique and…
- Trial name
- NCT06503042
- Testing
- Chemotherapy combined with immunotherapy, Chemotherapy only
- Volunteers
- 100 people
- Sponsor
- Tang-Du Hospital
Resectable Non-small Cell Lung Cancer
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
This study uses a prospective cohort design.Subjects are randomly divided into three groups (A, B, C) before surgery. Group A gets 3 cycles of sintilimab + chemo, Group B gets 2 cycles + 1 cycle, and Group C gets 1 cycle + 2…
- Trial name
- NCT06485557
- Testing
- sintilimab plus platinum-based chemotherapy
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Small Cell Lung Cancer (SCLC)
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
This study is a randomized, open-label, multicenter exploratory research aiming to evaluate the efficacy and safety of Adebrelimab in combination with chemotherapy (etoposide and platinum-based therapy) as neoadjuvant treatment…
- Trial name
- NCT06485544
- Testing
- Adebrelimab + Etoposide + Platinum-based Therapy, Etoposide + Platinum-based Therapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tang-Du Hospital
SCLC
Adebrelimab + Apatinib in SCLC Maintenance Therapy
This prospective clinical study aims to evaluate and observe the efficacy and safety of Atezolizumab combined with Apatinib in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design.
- Trial name
- NCT06475209
- Testing
- Adebrelimab combined with Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Non-Small Cell Lung Cancer, Anti Angiogenesis
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
This is a Phase II, prospective, randomized, open label, controlled, multi-center study, aim to evaluate the activity of Tislelizumab and Anlotinib and chemotherapy compared with Tislelizumab and chemotherapy before surgery…
- Trial name
- NCT06475755
- Testing
- Immunochemotherapy combined with antiangiogenic, Immunochemotherapy
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Tang-Du Hospital
Gastric Cancer
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer.
- Trial name
- NCT06475417
- Testing
- Adebrelimab combined with DOS
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Tang-Du Hospital
Resectable Esophageal Squamous Cell Carcinoma
Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC
This study is an open-label, prospective, cohort clinical study to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in…
- Trial name
- NCT06475196
- Testing
- Sintilimab (PD-1 inhibitor)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Small Cell Lung Cancer
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum…
- Trial name
- NCT06467786
- Testing
- Irinotecan hydrochloride liposome injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tang-Du Hospital
Adenocarcinoma of Lung
Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter
The core purpose of this study is to investigate whether the extracellular volume (ECV) fraction measured in delay phase by dual energy computed tomography (DECT) can distinguish precancerous lesions from early-stage lung…
- Trial name
- NCT06441357
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tang-Du Hospital
Spontaneous Subarachnoid Hemorrhage
Baricitinib for the Lung Injury Following Spontaneous SAH
The present study is a randomized, parallel control, and double-blind trial designed to assess the efficacy of baricitinib in reducing the occurrence of pulmonary complications in patients with spontaneous subarachnoid hemorrhage…
- Trial name
- BLISS (NCT06439615)
- Testing
- Baricitinib 4 MG, Standard treatment
- Volunteers
- 100 people
- Sponsor
- Tang-Du Hospital
Tumor Microenvironment, Lung Squamous Cell Carcinoma
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
- Conditions
- Tumor Microenvironment, Lung Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06436040
- Testing
- Pathological response assessment
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M…
- Trial name
- NCT06352502
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Hepatic Cancer
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis.
- Trial name
- NCT06245785
- Testing
- transarterial chemoembolisation
- Where
- 2 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Tang-Du Hospital
Hepatic Carcinoma
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis.
- Trial name
- NCT06245798
- Testing
- transarterial chemoembolisation
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Tang-Du Hospital
Gastroesophageal-junction Cancer, Proximal Gastrectomy
A Clinical Study of Laparoscopic Proximal Gastrectomy Based on PTST(Parachute-tunnel- Style Technique) Esophagogastric Anastomose.
1. To evaluate the safety, simplicity and effectiveness of the gastric function (anti-reflux) preservation of the innovative "parachute-tunnel-style technique" (PTST) in laparoscopic proximal gastrectomy. 2.
- Conditions
- Gastroesophageal-junction Cancer, Proximal Gastrectomy, Gastroesophagostomy
- Trial name
- NCT06217991
- Testing
- PTST(parachute-tunnel-style technique)for esophagogastrostomy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tang-Du Hospital
Myasthenia Gravis, Generalized
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
To evaluate the safety and efficacy of tocilizumab in the treatment of generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study tMG(NCT05067348).
- Trial name
- tMG-E (NCT05716035)
- Testing
- Tocilizumab Injection
- Where
- 6 sites in China
- Volunteers
- 64 people
- Sponsor
- Tang-Du Hospital
Glioma
Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data
Accurately predicting the survival of pediatric glioma patients is crucial for informed clinical decision-making and selecting appropriate treatment strategies.
- Trial name
- NCT06199388
- Testing
- Survival state
- Where
- China
- Volunteers
- 9,532 people
- Sponsor
- Tang-Du Hospital
Gastric Cancer
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (sintilimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer…
- Trial name
- NCT06123455
- Testing
- Taurine, Sintilimab, XELOX regimen
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Intracerebral Hemorrhage
Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is a critical disease of public health importance. Inflammatory mechanisms play a significant role in ICH.
- Trial name
- FMIICH (NCT06087965)
- Testing
- Fingolimod
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Traumatic Brain Injury
ICP Threshold After Decompressive Craniectomy
Severe traumatic brain injury (sTBI) is a critical disease of public health importance. Increased intracranial play a significant role in the secondary injury of TBI. Reducing the ICP is helpful in reducing the mortality of sTBI.
- Trial name
- NCT06083792
- Volunteers
- 240 people
- Sponsor
- Tang-Du Hospital